Please select the desired project time frame:
- July 2026
- January 2026
- July 2025
- January 2025
- July 2024
- January 2024
- July 2023
- January 2023
- July 2022
- January 2022
- July 2021
- January 2021
- July 2020
- January 2020
- July 2019
- January 2019
- July 2018
- January 2018
- July 2017
- January 2017
- July 2016
- January 2016
- July 2015
- January 2015
- July 2014
- January 2014
- July 2013
- January 2013
- July 2012
- January 2012
- July 2011
- January 2011
- July 2010
- January 2010
- July 2009
- January 2009
- July 2008
- January 2008
- July 2007
- January 2007
- July 2006
- January 2006
- July 2005
- January 2005
- July 2004
- January 2004
- July 2003
- January 2003
- July 2002
- January 2002
- July 2001
- January 2001
Start of funding 01.07.2022
Advanced electrically conductive peptide-based microgel bioinks for engineered cardiac tissues
Prof. Dr. Felix B. Engel
Friedrich-Alexander-University of Erlangen-Nuremberg
Nephropathology
Prof. Dr. Sarah Heilshorn
Stanford University
Department of Materials Science & Engineering
Cardiovascular diseases (CVDs) are responsible for more than one-third of global deaths. In most cases, CVDs cause the loss of cardiomyocytes which humans cannot regenerate. The Engel lab works intensively on developing novel materials to improve the engineering of functional human cardiac tissues based on stem cells focusing on electroconductive hydrogels. The Heilshorn lab is world-renowned for developing a novel class of biomaterials entirely composed of synthetic peptides suitable for 3D bio-printing to imitate nature's nano- and microscale order for regenerative medicine. These novel biomaterials exhibit many of the critical properties required for tissue formation and function, including elasticity, proteolytic remodeling, as well as cell adhesion and signaling. Our collaboration aims at developing 3D bio-printed electrically conductive human cardiac tissues for drug testing as well as treatment of heart failure.